Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000950170-25-020833·Pelthos Therapeutics Inc.
Schedule 13G ownership disclosure
CHROMOCELL THERAPEUTICS CORP
Common Stock, par value $0.0001 per share · CUSIP: 171126105
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Ikarian Capital, LLC
Shares: 440,849 · Class: 7.3%
- Neil Shahrestani
Shares: 440,849 · Class: 7.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-020833
- Form type
- SCHEDULE 13G
- Filer
- Pelthos Therapeutics Inc.
- CIK
- CIK 1919246
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership